LYRA vs. ICAD, INO, LUCD, NTRB, BLAC, MODD, CLGN, OM, DXR, and MBOT
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include iCAD (ICAD), Inovio Pharmaceuticals (INO), Lucid Diagnostics (LUCD), Nutriband (NTRB), Bellevue Life Sciences Acquisition (BLAC), Modular Medical (MODD), CollPlant Biotechnologies (CLGN), Outset Medical (OM), Daxor (DXR), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs.
Lyra Therapeutics (NASDAQ:LYRA) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.
In the previous week, iCAD had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for iCAD and 0 mentions for Lyra Therapeutics. iCAD's average media sentiment score of 0.95 beat Lyra Therapeutics' score of 0.00 indicating that iCAD is being referred to more favorably in the news media.
iCAD received 204 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 62.13% of users gave iCAD an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote.
Lyra Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
iCAD has higher revenue and earnings than Lyra Therapeutics. iCAD is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lyra Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 2,260.97%. Given Lyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than iCAD.
iCAD has a net margin of -17.81% compared to Lyra Therapeutics' net margin of -6,635.76%. iCAD's return on equity of -15.65% beat Lyra Therapeutics' return on equity.
95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of iCAD shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Comparatively, 10.3% of iCAD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
iCAD beats Lyra Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 1/20/2025 by MarketBeat.com Staff
